<DOC>
	<DOCNO>NCT00595049</DOCNO>
	<brief_summary>The main purpose study investigate whether bosentan ( Tracleer® ) affect wall thickness pulmonary artery patient idiopathic pulmonary arterial hypertension ( iPAH ) PAH related systemic sclerosis ( PAH-SSc ) . The second purpose investigate bosentan affect enlargement small vessel lung response natural chemical patient iPAH PAH-SSc .</brief_summary>
	<brief_title>Pulmonary Artery Remodelling With Bosentan</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Inclusion Criteria : · Men woman &gt; 18 year age.· Symptomatic ( modify NYHA class III ) iPAH PAHSSc· PAH confirm right heart catheterization perform within 3 month enrolment mPAP &gt; 25 mmHg , PCWP &lt; 15 mmHg PVR &gt; 3 mmHg/l/min . Women childbearing potential must negative pretreatment pregnancy test use reliable method contraception study treatment 3 month study treatment termination . Bosentan naïve patient Exclusion Criteria : · PAH iPAH PAHSSc Significant vasoreactivity right heart catheterization define fall mPAP &lt; 40 mmHg decrease &gt; = 10 mmHg normal cardiac index ( &gt; = 2.5 l/min.m2 ) · Severe obstructive lung disease : FEV1/FVC &lt; 0.5 Severe restrictive lung disease : TLC &lt; 0.7 normal predict value Hemoglobin &lt; 75 % low limit normal range· Systolic blood pressure &lt; 85 mmHg Body weight &lt; 40 kg Pregnancy breastfeed Moderate severe hepatic impairment , i.e. , ChildPugh Class B C. Baseline aminotransferases , i.e. , aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3 time upper limit normal ( ULN ) range . Treatment iPAH PAHSSc within 1 month start study treatment , exclude warfarin acute administration vasodilator vascular reactivity test heart catheterization . Treatment epoprostenol prostacyclin analog iPAH PAHSSc within 1 month start study treatment Treatment glibenclamide ( glyburide ) , fluconazole ketoconazole ritonavir within 1 week start study treatment . Current treatment cyclosporine A tacrolimus Hypersensitivity bosentan excipients formulation . Patient receive investigational drug ( sildenafil ) within 3 month start study treatment Conditions prevent compliance protocol adherence therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>pulmonary</keyword>
	<keyword>arterial</keyword>
	<keyword>artery</keyword>
	<keyword>hypertension</keyword>
	<keyword>systemic</keyword>
	<keyword>sclerosis</keyword>
	<keyword>scleroderma</keyword>
	<keyword>remodelling</keyword>
	<keyword>bosentan</keyword>
	<keyword>tracleer</keyword>
	<keyword>intravascular</keyword>
</DOC>